- Masahiro Toda
- … show all 1 hide
Purchase on Springer.com
$29.95 / €24.95 / £19.95*
* Final gross prices may vary according to local VAT.
Because several antigenic peptides of human tumors that are recognized by T-lymphocytes have been identified, immune responses against cancer can now be artificially manipulated. Furthermore, since T-lymphocytes have been found to play an important role in the rejection of tumors by the host and also to have antigen-specific proliferative potentials and memory mechanisms, T-lymphocytes are thought to play a central role in cancer vaccination. Although multidisciplinary therapies have been attempted for the treatment of gliomas, the results remain unsatisfactory. For the development of new therapies against gliomas, it is required to identify tumor antigens as targets for specific immunotherapy. In this chapter, recent progress in research on glioma antigens is described.
Supplementary Material (0)
- Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev 2003; 3:666–675. CrossRef
- Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281–287. CrossRef
- Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380–384. CrossRef
- Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26:3661–3678. CrossRef
- Bernard-Marty C, Lebrun F, Awada A et al. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006; 66:1577–1591. CrossRef
- Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotech 2005; 23:1147–1157. CrossRef
- Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997; 16:313–339. CrossRef
- Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science 1994 Apr 29;264(5159):716–719. CrossRef
- Hogan KT, Eisinger DP, Cupp SB, 3rd et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T-lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res 1998; 58:5144–5150.
- van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. J Immunol 2007 Mar 1;178(5):2617–2621.
- Iizuka Y, Kojima H, Kobata T et al. Identification of a glioma antigen, GARC-1, using cytotoxic T-lymphocytes induced by HSV cancer vaccine. Int J Cancer 2006; 118:942–949. CrossRef
- Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9:709–716. CrossRef
- Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914–1918. CrossRef
- Ueda R, Iizuka Y, Yoshida K et al. Identification of a human glioma antigen, SOX6, recognized by patients’ sera. Oncogene 2004; 23:1420–1427. CrossRef
- Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810–11813. CrossRef
- Fischer U, Struss AK, Hemmer D et al. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 2001; 126:206–213. CrossRef
- Struss AK, Romeike BF, Munnia A et al. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001; 20:4107–4114. CrossRef
- Okada H, Attanucci J, Giezeman-Smits KM et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res 2001; 61:2625–2631.
- Ueda R, Kinoshita E, Ito R et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int J Cancer 2008; 122:2274–2279. CrossRef
- Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J 1997; 44:43–51. CrossRef
- Ueda R, Yoshida K, Kawakami Y et al. Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol 2004; 21:35–38. CrossRef
- Chi DD, Merchant RE, Rand R et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150:2143–2152.
- Liu G, Ying H, Zeng G et al. HER-2, gp100 and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T-cells. Cancer Res 2004; 64:4980–4986. CrossRef
- Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9:4247–4254.
- Okano F, Storkus WJ, Chambers WH et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T-lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 2002; 8:2851–2855.
- Hatano M, Eguchi J, Tatsumi T et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005 Aug;7(8):717–722. CrossRef
- Jin M, Komohara Y, Shichijo S et al. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24+ malignant glioma patients. Oncol Rep 2008; 19:1277–1283.
- Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 2004; 27:220–226. CrossRef
- Hashiba T, Izumoto S, Kagawa N et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir 2007; 47:165–170; discussion 170. CrossRef
- Nonaka Y, Tsuda N, Shichijo S et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T-lymphocytes from patients with brain tumors. Tissue Antigens 2002; 60:319–327. CrossRef
- Murayama K, Kobayashi T, Imaizumi T et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T-lymphocytes by its peptides. J Immunother 2000; 23:511–518. CrossRef
- Schmitz M, Wehner R, Stevanovic S et al. Identification of a naturally processed T-cell epitope derived from the glioma-associated protein SOX11. Cancer Lett 2007; 245:331–336. CrossRef
- Harada M, Ishihara Y, Itoh K et al. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T-lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep 2007; 17:629–636.
- Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108:963–971. CrossRef
- Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11:5900–5911. CrossRef
- Toda M. Cancer vaccine for brain tumors and brain tumor antigens. Cancer Therapy 2004; 2:21–26.
- Zalutsky MR, Moseley RP, Benjamin JC et al. Monoclonal antibody and F(ab’)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 1990; 50:4105–4110.
- Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55:3140–3148.
- Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev of Anticancer Ther 2007; 7:675–687. CrossRef
- Wikstrand CJ, Cole VR, Crotty LE et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 2002; 50:639–652. CrossRef
- Woodward WA, Sulman EP. Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 2008; 27:459–470. CrossRef
- Toda M, Iizuka Y, Yu W et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001; 34:1–7. CrossRef
- Tohyama T, Lee VM, Rorke LB et al. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Investi 1992; 66:303–313.
- Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740–745. CrossRef
About this Chapter
- Glioma Antigen
- Book Title
- Book Subtitle
- Immunotherapeutic Approaches
- Book Part
- Part II
- pp 77-84
- Print ISBN
- Online ISBN
- Series Title
- Advances in Experimental Medicine and Biology
- Series Volume
- Series ISSN
- Springer New York
- Copyright Holder
- Springer Science+Business Media, LLC
- Additional Links
- Industry Sectors
- eBook Packages
To view the rest of this content please follow the download PDF link above.